Elamari Saloua, Motaib Imane, Zbiri Saad, Elaidaoui Karim, Chadli Asmaa, Elkettani Chafik
Department of Endocrinology, Diabetology, Metabolic Disease and Nutrition, Mohammed VI University of Health Sciences, Casablanca, Morocco.
Laboratory of Medical Evaluation and Health Economics, International School of Public Health, Mohammed VI University of Health Sciences, Casablanca, Morocco.
Pan Afr Med J. 2020 Sep 8;37:32. doi: 10.11604/pamj.2020.37.32.25192. eCollection 2020.
Diabetes is considered a risk factor for complications due to COVID-19. In order to clarify this association, we are exploring the characteristics, the clinical signs, the outcomes and death in diabetic patients with COVID-19. In this retrospective observational study we are evaluating the demographic characteristics, the comorbidities of the patients, the clinical signs of the infection, the signs of clinical severity, the biological assessment at admission, the treatment, the outcomes and the deaths of 133 patients with COVID-19, of which 25 (19,4%) had diabetes. In the compared COVID-19 patients, with and without diabetes, the patients with diabetes were older, had higher blood pressure and more cardio-vascular diseases. Severe forms were more present in diabetic patients (56% versus 27.1%). Weight loss was higher in diabetic patients (6kg versus 3kg). Biologically, diabetic patients had higher levels of C-reactive protein (28 versus 5.8mg/l), procalcitonin (0.28 versus 0,13ng/l), ferritin (501 versus 140ng/ml), lactic dehydrogenase (268 versus 226IU/l) and of D. dimer (665 versus 444μg/l). Diabetic patients required more oxygen therapy (60% versus 26.9%), more mechanical ventilation (20% versus 8.3%) and more frequent admission to the intensive care unit (60% versus 27.8%). They presented more thromboembolic complications (12% versus 9%) but there were not significant differences in the other outcomes and in death rates. The excess of morbidity and mortality due to diabetes was still not fully clarified; the role of demographic factors, the interaction of mediations with ACE-2 receptors and the role of co-morbidities will all need to be studied in order to identify the patient at risk profile, i.e. who can develop severe forms of the diseases and more outcomes. The early identification of a possible hyper inflammation could be very valuable. More attention should be paid to patients with COVID-19 with diabetes because they are at a high risk of complications.
糖尿病被认为是感染新型冠状病毒肺炎(COVID - 19)引发并发症的一个风险因素。为了阐明这种关联,我们正在探究COVID - 19糖尿病患者的特征、临床症状、治疗结果及死亡情况。在这项回顾性观察研究中,我们评估了133例COVID - 19患者的人口统计学特征、合并症、感染的临床症状、临床严重程度体征、入院时的生物学评估、治疗情况、治疗结果及死亡情况,其中25例(19.4%)患有糖尿病。在对比的有糖尿病和无糖尿病的COVID - 19患者中,糖尿病患者年龄更大,血压更高,心血管疾病更多。糖尿病患者中重症类型更多见(56% 对27.1%)。糖尿病患者体重减轻更多(6千克对3千克)。从生物学角度看,糖尿病患者的C反应蛋白水平更高(28对5.8毫克/升)、降钙素原水平更高(0.28对0.13纳克/升)、铁蛋白水平更高(501对140纳克/毫升)、乳酸脱氢酶水平更高(268对226国际单位/升)以及D - 二聚体水平更高(665对444微克/升)。糖尿病患者需要更多的氧疗(60%对26.9%)、更多的机械通气(20%对8.3%),且更频繁地入住重症监护病房(60%对27.8%)。他们出现更多的血栓栓塞并发症(12%对9%),但在其他治疗结果及死亡率方面无显著差异。糖尿病导致的发病率和死亡率过高的情况仍未完全阐明;人口统计学因素的作用、介导物与血管紧张素转换酶2(ACE - 2)受体的相互作用以及合并症的作用都需要进行研究,以便确定高危患者群体,即哪些人可能发展为重症疾病及出现更多不良后果。尽早识别可能存在的过度炎症反应可能非常有价值。对于患有COVID - 19的糖尿病患者应给予更多关注,因为他们发生并发症的风险很高。